These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19782351)

  • 1. Different phenotypes of polycystic ovary syndrome by Rotterdam criteria are differently steroidogenic but similarly insulin resistant.
    Wang Y; Qu J; Wu X; Hou L; Erkkola R; Wang Y
    Fertil Steril; 2010 Mar; 93(4):1362-5. PubMed ID: 19782351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria.
    Kauffman RP; Baker TE; Baker VM; DiMarino P; Castracane VD
    Am J Obstet Gynecol; 2008 Jun; 198(6):670.e1-7; discussion 670.e7-10. PubMed ID: 18355776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical and laboratory characteristics of cases with polycystic ovarian syndrome based on Rotterdam's criteria and women whose only clinical signs are oligo/anovulation or hirsutism.
    Hassa H; Tanir HM; Yildiz Z
    Arch Gynecol Obstet; 2006 Jul; 274(4):227-32. PubMed ID: 16691383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indicators for metabolic disturbances in anovulatory women with polycystic ovary syndrome diagnosed according to the Rotterdam consensus criteria.
    Goverde AJ; van Koert AJ; Eijkemans MJ; Knauff EA; Westerveld HE; Fauser BC; Broekmans FJ
    Hum Reprod; 2009 Mar; 24(3):710-7. PubMed ID: 19095675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS).
    Diamanti-Kandarakis E; Katsikis I; Piperi C; Kandaraki E; Piouka A; Papavassiliou AG; Panidis D
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):634-41. PubMed ID: 18363886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCOS according to the Rotterdam consensus criteria: Change in prevalence among WHO-II anovulation and association with metabolic factors.
    Broekmans FJ; Knauff EA; Valkenburg O; Laven JS; Eijkemans MJ; Fauser BC
    BJOG; 2006 Oct; 113(10):1210-7. PubMed ID: 16972863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evaluation of metabolic parameters and insulin sensitivity for a more robust diagnosis of the polycystic ovary syndrome.
    Amato MC; Galluzzo A; Finocchiaro S; Criscimanna A; Giordano C
    Clin Endocrinol (Oxf); 2008 Jul; 69(1):52-60. PubMed ID: 18034780
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Androgens and insulin--two key players in polycystic ovary syndrome. Recent concepts in the pathophysiology and genetics of polycystic ovary syndrome.
    Schuring AN; Schulte N; Sonntag B; Kiesel L
    Gynakol Geburtshilfliche Rundsch; 2008; 48(1):9-15. PubMed ID: 18209494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature.
    Azziz R
    J Clin Endocrinol Metab; 2006 Mar; 91(3):781-5. PubMed ID: 16418211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The reproductive phenotype in polycystic ovary syndrome.
    Chang RJ
    Nat Clin Pract Endocrinol Metab; 2007 Oct; 3(10):688-95. PubMed ID: 17893687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of different phenotypes of polycystic ovary syndrome in a Bulgarian population.
    Pehlivanov B; Orbetzova M
    Gynecol Endocrinol; 2007 Oct; 23(10):604-9. PubMed ID: 17852429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ovarian insulin resistance and insulin sensitizer effect on polycystic ovary syndrome].
    Wu XK; Risto E
    Zhonghua Fu Chan Ke Za Zhi; 2004 Dec; 39(12):804-8. PubMed ID: 15733404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria.
    Shroff R; Syrop CH; Davis W; Van Voorhis BJ; Dokras A
    Fertil Steril; 2007 Nov; 88(5):1389-95. PubMed ID: 17462641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis, phenotype, and prevalence of polycystic ovary syndrome.
    Carmina E; Azziz R
    Fertil Steril; 2006 Jul; 86 Suppl 1():S7-8. PubMed ID: 16798288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current diagnosis of polycystic ovary syndrome: expanding the phenotype but generating new questions].
    Merino P; Schulin-Zeuthen C; Codner E
    Rev Med Chil; 2009 Aug; 137(8):1071-80. PubMed ID: 19915773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationships between AMH, androgens, insulin resistance and basal ovarian follicular status in non-obese subfertile women with and without polycystic ovary syndrome.
    Nardo LG; Yates AP; Roberts SA; Pemberton P; Laing I
    Hum Reprod; 2009 Nov; 24(11):2917-23. PubMed ID: 19617605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phenotypic characteristics according to insulin sensitivity in non-obese Korean women with polycystic ovary syndrome.
    Park HR; Choi Y; Lee HJ; Oh JY; Hong YS; Sung YA
    Diabetes Res Clin Pract; 2007 Sep; 77 Suppl 1():S233-7. PubMed ID: 17606307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic criteria in polycystic ovary syndrome.
    Legro RS
    Semin Reprod Med; 2003 Aug; 21(3):267-75. PubMed ID: 14593549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polycystic ovary syndrome and type 2 diabetes mellitus.
    De Leo V; Musacchio MC; Morgante G; La Marca A; Petraglia F
    Minerva Ginecol; 2004 Feb; 56(1):53-62. PubMed ID: 14973410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic determinants of insulin action in polycystic ovary syndrome.
    Haap M; Machicao F; Stefan N; Thamer C; Tschritter O; Schnuck F; Wallwiener D; Stumvoll M; Häring HU; Fritsche A
    Exp Clin Endocrinol Diabetes; 2005 May; 113(5):275-81. PubMed ID: 15926113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.